Indrani Lall Franchini sold $272k of ALNY
EVP, CLO & Secretary at ALNYLAM PHARMACEUTICALS, INC.. 1,591 shares at an average of $170.99, traded Feb 2, 2024, filed Feb 5, 2024.
Score components
- +15RoleOfficer
- +13Trade size$272k at market
- +10Share of holdings soldSold 31% of holdings
- +15Cluster5 insiders selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001735276-24-000002, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 1, 2024 | MOption exercise Common Stock | +5,175 | $0.00 | $0 | 5,175 | Feb 5, 2024 |
| Feb 2, 2024 | SOpen-market sale Common Stock | -502 | $170.01 | $85k | 4,673 | Feb 5, 2024 |
| Feb 2, 2024 | SOpen-market sale Common Stock | -820 | $171.14 | $140k | 3,853 | Feb 5, 2024 |
| Feb 2, 2024 | SOpen-market sale Common Stock | -269 | $172.38 | $46k | 3,584 | Feb 5, 2024 |
| Feb 1, 2024 | MOption exercise Restricted Stock Unitsderivative | -5,175 | $0.00 | $0 | 5,175 | Feb 5, 2024 |
Related signals
Other insiders at ALNYLAM PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 36Weak | ALNYsell ALNYLAM PHARMACEUTICALS, INC. | Bryan Supran EVP, CLO and Secretary | $399k 1,758 shares | -12% | |
| 25Weak | ALNYLAM PHARMACEUTICALS, INC. | David E I Pyott director | $1.1M 3,830 shares | -71% | |
| 30Weak | ALNYLAM PHARMACEUTICALS, INC. | Melissa McLaughlin Chief Human Resources Officer | $1.3M 3,910 shares | -29% | |
| 26Weak | ALNYLAM PHARMACEUTICALS, INC. | Kevin Joseph Fitzgerald CSO & EVP, Head of Research | $418k 1,291 shares | -6% | |
| 51Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $746k 2,309 shares | -6% | |
| 59Moderate | ALNYLAM PHARMACEUTICALS, INC. | Jeffrey V. Poulton EVP, Chief Financial Officer | $797k 2,468 shares | -4% | |
| 64Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $948k 2,933 shares | -3% | |
| 40Moderate | ALNYLAM PHARMACEUTICALS, INC. | Pushkal Garg EVP Chief R&D | $1.5M 4,713 shares | -20% | |
| 65Notable | ALNYLAM PHARMACEUTICALS, INC. | Yvonne Greenstreet Chief Executive Officer | $2.2M 6,799 shares | -6% | |
| 48Moderate | ALNYLAM PHARMACEUTICALS, INC. | Tolga Tanguler EVP, Chief Commercial Officer | $524k 1,598 shares | -4% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.